DIET--ENDOCRINE STUDY OF BREAST AND PROSTATE CANCER

饮食——乳腺癌和前列腺癌的内分泌研究

• 批准号: 6072372
• 负责人: WENDY DEMARK-WAHNEFRIED
• 金额: $ 8.82万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-09-30 至 2001-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6072372
• 关键词: basal metabolism; blood chemistry; body composition; body physical activity; body weight; breast neoplasms; caloric dietary content; cyclophosphamide; diet therapy; endocrinology; estradiol; female; fluorouracil; globulins; human subject; longitudinal human study; neoplasm /cancer chemotherapy; neoplasm /cancer education; nutrition related tag; prostate neoplasms; thermogenesis; weight control; women's health

Cancers of the prostate and breast constitute almost one-third of all cancers in the United States. These neoplasms, which have been characterized as hormonally-linked, are the leading cancers in American men and women. Despite obvious gender differences, these cancers share a substantial common ground [eg. similar rates of incidence, parallel epidemiologic relationships to various factors (high fat diet, obesity, etc.) and analogous proposed pathways of etiopathogenesis]. An academic award is sought in efforts to broaden the applicant's understanding of these hormone-related cancers. This effort is sponsored by primary mentor Barbara Rimer, Dr.PH, with planned experiences in relevant programs directed by James Iglehart, M.D., Eric Winer, M.D., Claude Hughes, M.D., Ph.D., and Cary Robertson, M.D. of Duke, and University of North Carolina's Paul Godley, M.D., Ph.D. and Boyd Switzer, Ph.D. The ultimate goal of the proposed program is to provide the applicant with a working knowledge-base in prostate and breast cancer, endocrinology and molecular biology/genetic regulation - a knowledge base that would complement her skills as a nutritionist and enable her to identify appropriate intermediate end points for nutrition intervention in these areas. This training will afford the applicant the springboard necessary for translational research in these areas and the opportunity to become an independent investigator in preventive oncology. A research project is a focal piece of the proposed training, and will permit the investigator to broaden and continue her interest in diet, body fat and its distribution, and their relationship to the continuum of neoplastic disease. The study is entitled "Exploration and Intervention in Weight Gain Associated with Adjuvant Chemotherapy for Breast Cancer." Weight gain is a common side effect in women receiving adjuvant chemotherapy for breast cancer - one that has been consistently reported throughout the past twenty years. For some therapies, gains of over 22 pounds are seen in one out of four women. This weight gain may be undesirable. First, it may have a profoundly negative psychosocial impact on a group of patients who may already have a compromised sense of self esteem. Second, recent findings suggest that weight gain during therapy is associated with decreased survival. Although weight gain during adjuvant chemotherapy for breast cancer is well-appreciated clinically, little research has been conducted to investigate the underlying mechanisms of this energy imbalance. Appropriate interventions cannot be developed until this is known. The specific aims of the proposed research are as follows: 1) to quantitate changes in energy intake and specific components of energy expenditure (ie. resting metabolic rate, diet-induced thermogenesis and physical activity) in 100 premenopausal breast cancer patients receiving adjuvant chemotherapy [six month regimens of cyclophosphamide + methotrexate + 5 fluorouracil (CMF) or cyclophosphamide + doxarubacin + 5 fluorouracil (CAF)] and 2) to use the findings of this proposed research to develop an appropriate intervention to prevent weight gain in this population. This research avenue has the potential to increase both the quantity and quality of life for breast cancer patients undergoing adjuvant chemotherapy, while making an overall contribution to our understanding of body weight and cancer.

前列腺癌和乳腺癌几乎占所有癌症的三分之一 美国的癌症。这些肿瘤，已 与荷尔蒙相关的癌症是美国的主要癌症 男女。尽管存在明显的性别差异，但这些癌症有一个共同点 实质性共同点[例如。相似的发生率，平行 流行病学与各种因素的关系（高脂肪饮食、肥胖、 等）和类似的发病机制提出的途径]。一位学者 寻求奖项是为了努力扩大申请人的理解 这些与激素相关的癌症。这项工作由主要导师赞助 Barbara Rimer，博士，具有相关项目的计划经验 由 James Iglehart（医学博士）、Eric Winer（医学博士）、Claude Hughes（医学博士）执导， 杜克大学和北方大学医学博士卡里·罗伯逊 (Cary Robertson) 卡罗莱纳州的 Paul Godley，医学博士、哲学博士和博伊德·斯威策博士终极 拟议计划的目标是为申请人提供工作 前列腺癌和乳腺癌、内分泌学和分子学知识库 生物学/遗传调控——一个可以补充她的知识库 作为营养师的技能，使她能够确定适当的 这些领域营养干预的中间终点。这 培训将为申请人提供必要的跳板 这些领域的转化研究以及成为一名 预防肿瘤学的独立研究者。 研究项目是拟议培训的重点部分，并将 允许研究者扩大并继续她对饮食、身体的兴趣 脂肪及其分布，以及它们与连续体的关系 肿瘤性疾病。该研究的标题是“探索与干预 体重增加与乳腺癌辅助化疗相关。” 体重增加是接受辅助治疗的女性常见的副作用 乳腺癌化疗——一种已被持续报道的疗法 纵观过去的二十年。对于某些疗法，增益超过 22 四分之一的女性患有体重。这种体重增加可能是 不受欢迎的。 首先，它可能会产生深远的负面心理影响 针对一群自我意识可能已经受损的患者 尊重。其次，最近的研究结果表明，治疗期间体重增加与 与生存率下降有关。虽然辅助治疗期间体重增加 乳腺癌的化疗在临床上得到广泛认可，但目前应用较少 已经进行了研究以调查其潜在机制 这种能量不平衡。在以下情况之前无法制定适当的干预措施： 这是众所周知的。 本研究的具体目标如下：1） 量化能量摄入和能量特定成分的变化 支出（即静息代谢率、饮食诱导的生热作用和 体力活动）在 100 名接受治疗的绝经前乳腺癌患者中 辅助化疗[六个月的环磷酰胺方案+ 甲氨蝶呤 + 5 氟尿嘧啶 (CMF) 或环磷酰胺 + 多柔巴星 + 5 氟尿嘧啶 (CAF)] 和 2) 使用本拟议研究的结果 制定适当的干预措施来防止体重增加 人口。这一研究途径有可能提高 乳腺癌患者的生活数量和质量 辅助化疗，同时为我们的整体贡献 了解体重和癌症。

项目成果

Effect of mammalian lignans on the growth of prostate cancer cell lines.

• 发表时间: 2001-11
• 期刊: Anticancer research
• 影响因子: 2
• 作者: Xuehua Lin;B. Switzer;W. Demark-Wahnefried

Preventing sarcopenic obesity among breast cancer patients who receive adjuvant chemotherapy: results of a feasibility study.

预防接受辅助化疗的乳腺癌患者出现肌肉减少性肥胖：可行性研究的结果。

• 发表时间: 2002
• 期刊: Clinical exercise physiology
• 作者: Demark-Wahnefried,Wendy;Kenyon,AnneJacobs;Eberle,Pamela;Skye,Ann;Kraus,WilliamE
• 通讯作者: Kraus,WilliamE